Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 3;3(1):e210008.
doi: 10.1148/ryct.2021210008. eCollection 2021 Feb.

Axillary Lymphadenopathy After mRNA COVID-19 Vaccination

Richard W Ahn  1 , Ann R Mootz  1 , Cecelia C Brewington  1 , Suhny Abbara  1
Affiliations

Axillary Lymphadenopathy After mRNA COVID-19 Vaccination

Richard W Ahn et al. Radiol Cardiothorac Imaging. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. Richard Ahn owns 20 shares of Pfizer stock. Dr. Richard Ahn has no other relationship and no funding from Pfizer. Dr. Suhny Abbara reports royalty income from Elsevier/Amirsys. Dr. Cecelia Brewington reports grant funding from Cannon Medical Systems. Dr. Ann Mootz reports no conflicts of interest.

Figures

Axial CTA-MIP images demonstrating normal right axillary lymph nodes (A, open arrow) and unilateral left axillary lymphadenopathy (A, closed arrow) 7-days after administration of the second dose of an mRNA-COVID-19 vaccine in a 32-year-old man. The short axis of the lymph nodes measured up to 1.5 cm. Axial breast cancer screening MRI image (B, closed arrow) demonstrating a 2 cm left axillary lymph node seen 13 days after ipsilateral administration of the first dose of an mRNA COVID-19 vaccine in a 34-year-old female. Axillary ultrasound of the same patient (C) demonstrates a 2 cm likely reactive lymph node with diffuse cortical thickening. Follow-up imaging in 4-6 weeks was recommended. Axial CT image in a 39-year-old woman demonstrating normal left axillary lymph nodes (D, open arrow). Axial breast cancer screening MRI image ∼ 200 days later in the same patient (E, closed arrow) demonstrating new left axillary adenopathy measuring up to 1.4 cm in short axis 8 days after an mRNA COVID-19 vaccination. The patient was recalled for left axillary ultrasound. The involved lymph nodes in all three cases typically drain the arm (1). All patients were asymptomatic. Lymphadenopathy was reported in 64 patients receiving the BNT162b2-mRNA-COVID-19 vaccine compared to 6 in the placebo group (2). This potential association should be recognized in lung cancer screening, oncologic imaging and breast imaging as it is a differential consideration in workup of metastatic disease. While these cases are observational, further studies may investigate their association with a robust immune response.
Figure.
Axial CTA-MIP images demonstrating normal right axillary lymph nodes (A, open arrow) and unilateral left axillary lymphadenopathy (A, closed arrow) 7-days after administration of the second dose of an mRNA-COVID-19 vaccine in a 32-year-old man. The short axis of the lymph nodes measured up to 1.5 cm. Axial breast cancer screening MRI image (B, closed arrow) demonstrating a 2 cm left axillary lymph node seen 13 days after ipsilateral administration of the first dose of an mRNA COVID-19 vaccine in a 34-year-old female. Axillary ultrasound of the same patient (C) demonstrates a 2 cm likely reactive lymph node with diffuse cortical thickening. Follow-up imaging in 4-6 weeks was recommended. Axial CT image in a 39-year-old woman demonstrating normal left axillary lymph nodes (D, open arrow). Axial breast cancer screening MRI image ∼ 200 days later in the same patient (E, closed arrow) demonstrating new left axillary adenopathy measuring up to 1.4 cm in short axis 8 days after an mRNA COVID-19 vaccination. The patient was recalled for left axillary ultrasound. The involved lymph nodes in all three cases typically drain the arm (1). All patients were asymptomatic. Lymphadenopathy was reported in 64 patients receiving the BNT162b2-mRNA-COVID-19 vaccine compared to 6 in the placebo group (2). This potential association should be recognized in lung cancer screening, oncologic imaging and breast imaging as it is a differential consideration in workup of metastatic disease. While these cases are observational, further studies may investigate their association with a robust immune response.
See this image and copyright information in PMC

References

    1. Ecanow JS, Abe H, Newstead GM, Ecanow DB, Jeske JM. Axillary Staging of Breast Cancer: What the Radiologist Should Know. Radiographics. 2013;33(6):1589-612. doi: 10.1148/rg.336125060. PubMed PMID: 24108553. - PubMed
    1. Pfizer-BioNTech COVID-19 Vaccine; FDA Briefing Document . Vaccines and Related Biological Products Advisory Committee Meeting. December, 10 2020

LinkOut - more resources